Dana Farber Cancer Institute

Site:	Dana Farber Cancer Institute	Go to their website
Address:	450 Brookline Ave
City:	Boston
State:	MA
Zip:	02215-5450
Country:	USA

70 trials at this site

Phase [asc]	Trial	Trial Status	Site Status	Drug	NCT#
1	Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)	Completed	Closed	IPI-504	NCT00276302
1	Phase I (PH I) Mad Refractory Solid Tumor Study	Completed	Closed	Dasatinib (BMS-354825)	NCT00099606
1	Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	STA-9090	NCT00688116
1	Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.	Ongoing, but not recruiting	Closed	AUY922	NCT00526045
1	Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors	Ongoing, but not recruiting	Closed	XL147	NCT00486135
1	A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable	Ongoing, but not recruiting	Closed	GDC-0941	NCT00876109
1	Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)	Completed	Closed	Imatinib and Nilotinib	NCT00135005
1	A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer	Completed	Closed	BGT226	NCT00600275
1	Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors	Completed	Closed	AT13387	NCT00878423
1	RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms	Ongoing, but not recruiting	Closed	CP-751,871 + RAD001	NCT00927966
1	A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma	Ongoing, but not recruiting	Closed	GDC-0980	NCT00854126
1	A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors	Completed	Closed	GDC-0941 + GDC-0973	NCT00996892
1	Safety Study of PLX108-01 in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 (PLX108-01)	NCT01004861
1	A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients	Completed	Closed	Imatinib + BKM120	NCT01468688
1	A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma	Completed	Closed	GDC-0980	NCT00854152
1	A Non-randomized, Open-label, Single-center Phase Ib Study of Short Cycles of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors: SURE Trial	Ongoing, but not recruiting	Closed	Sunitinib + Regorafenib	NCT02164240
1	Phase 1 Study of OSI-930 in Cancer Patients	Completed	Closed	osi-930	NCT00513851
1	Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Active, not recruiting	Closed	Nivolumab + BMS-986016	NCT01968109
1	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Active, not recruiting	Closed	CB-839	NCT02071862
1	PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors	Completed	Closed	PLX9486 + PLX3397	NCT02401815

Dana Farber Cancer Institute

70 trials at this site

Page 1 of 4 | Next | Last